Dr. Kieran is Clinical Trial Lead, Pediatrics Program, Oncology Clinical Development, Bristol-Myers Squibb. He received his PhD in 1983 from the University of Alberta, Edmonton, Canada, and his MD in 1986 from the University of Calgary. After a post-doc in molecular biology in Paris, France and pediatric residency at McGill University in Montreal, he completed a second post-doc in signal transdution at Children’s Hospital Boston. Dr. Kieran became Director of Pediatric Medical Neuro-Oncology at Dana-Farber Boston Children’s Cancer and Blood Disorders Center in 1999. Dr. Kieran’s primary research interest was the genomic identification of mutations and development of new targeted therapies for children with brain tumors. He has a particular focus on tumors of glial origin and the identification of the biology that leads to their growth. His laboratory focused on the immune microenvironment of tumors while the clinical program centered on the initiation of early phase trials for brain tumors based on the improved understanding of their biology and incorporation of personalized approaches such as targeted therapies, biologic therapies, immune therapy and gene therapy. Dr. Kieran has been a member of the Society for Neuro-Oncology, the Society of Pediatric Research, and the American Society for Clinical Oncology. He was the pediatric editor of Neuro-Oncology and served on the Editorial Board of Child’s Nervous System. Until his move to BMS in mid 2018, Dr. Kieran also led the Response Assessment in Pediatric NeuroOncology Committee (RAPNO), which is dedicated to improving the criteria on which new therapies are assessed.